Pharmacotherapy for hypertensive urgency and emergency in COVID-19 patients

Fabio Angeli, Paolo Verdecchia and Gianpaolo Reboldi

ABSTRACT

Introduction: Hypertension is a common chronic disorder in patients hospitalized for coronavirus disease 2019 (COVID-19). Furthermore, an exaggerated cardiovascular response with persistently raised blood pressure during hospitalization seems independently associated with in-hospital all-cause mortality, intensive care unit admission and heart failure. However, the real burden of elevated blood pressure during the acute phase of COVID-19 remains undefined.

Areas covered: The authors review the available evidence on the pharmacotherapy for the treatment of acute elevations in blood pressure (including hypertensive urgency and emergency) in COVID-19 patients.

Expert opinion: Acute elevations in blood pressure and unstable in-hospital blood pressure may be associated with organ damage and worse outcome in patients with COVID-19. In this setting, hypertensive emergencies require immediate reduction in blood pressure through intravenous treatment according to specific features and goals. Conversely, hypertensive urgencies usually require solely oral treatment. Diuretics, beta-blockers, renin-angiotensin-aldosterone system inhibitors, and calcium channel blockers may be of benefit in treating COVID-19 patients with elevated blood pressure values.

1. Introduction

Studies in patients admitted to hospital for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection showed that comorbidities increase the risk of severe clinical outcomes [1–4].

The United States Centers for Disease Control and Prevention (CDC) released a list of well-established risk factors that have been associated with severe coronavirus disease 2019 (COVID-19) as documented in observational studies, systematic reviews and meta-analyses [5]. The list includes older age, hypertension, cancer, previous cerebrovascular disease, history of cardiovascular disease, chronic kidney disease, diabetes mellitus, and obesity. Among these, one of the most common comorbidities among COVID-19 patients is hypertension [1,2].

In a clinical study involving 5700 hospitalized COVID-19 patients from New York area in the United States, hypertension was the most common comorbidity (prevalence of 56.6%) and it was associated with an increased risk of death, intensive care unit admission, invasive ventilation, and renal replacement therapy [6]. These results have been confirmed in a meta-analysis of 7 clinical studies including 1576 COVID-19 infected patients. It showed that the most prevalent comorbidity was hypertension (21.1%, 95% confidence interval [CI]: 13.0–27.2%) [7] and that patients with hypertension were at increased risk of severe COVID-19 (odds ratio [OR]: 2.49; 95% CI: 1.98–3.12) along with a higher risk of mortality (OR: 2.42; 95% CI: 1.51–3.90) [8]. Furthermore, an exaggerated cardiovascular response with persistently elevated blood pressure (BP) and high BP variability during hospitalization are independently associated with in-hospital all-cause mortality, intensive care unit admission, and heart failure [9,10].

These findings indicate that acute elevations in BP and unstable in-hospital BP are significant predictors of worse outcome in COVID-19 [9,10].

Although hypertension seems to be linked to the pathogenesis of COVID-19 and acute elevations in BP can result in acute worsening of hypertension-mediated organ damage and more unfavorable outcome [9], the real burden of elevated BP during the acute phase of COVID-19 remains undefined. Furthermore, there are conflicting views of the epidemiology in academic literature.

The main aim of our narrative review was to summarize available evidences on the pharmacotherapy for the treatment of acute elevations of BP, including hypertensive urgency and emergency, in COVID-19 patients. For this purpose, we conducted a systematic review of clinical and experimental studies according to established methods [11,12]. Literature searches were conducted using PubMed, Scopus, EMBASE, Web of Science, and Google Scholar databases. We searched for eligible studies using research Methodology Filters [11,12]. The following research terms were used: ‘COVID-19, SARS-CoV-2; blood pressure; hypertensive emergency; hypertensive urgency,
high blood pressure, hypertension, blood pressure lowering-drugs.

2. Definition of hypertensive urgencies and emergencies

According to current Guidelines [13], hypertensive emergencies are defined as the development of marked elevation in BP values associated with signs or symptoms of acute hypertension-mediated target-organ damages [13]. They require immediate, but careful, reduction in BP to promote regression of organ damage or to limit its extension [13–15]. Key target organs of hypertensive emergencies are the heart, brain, large arteries, kidneys, and retina [13]. Target-organ damages include cardiac ischemia, advanced retinopathy (as defined by the presence of flame-shaped hemorrhages, cotton wool spots, or papilledema), hypertensive encephalopathy, acute stroke (ischemic or hemorrhagic), acute cardiogenic pulmonary edema, acute aortic disease, eclampsia and severe pre-eclampsia/HELLP syndrome (Hemolysis, Elevated Liver enzymes and Low Platelets), acute hypertensive nephrosclerosis, and thrombotic microangiopathy (Coombs-negative hemolysis and thrombocytopenia in the absence of another plausible cause) [13,16–20].

Conversely, elevated BP (systolic pressure ≥ 180 mmHg and/or diastolic pressure ≥ 120 mmHg) without acute end-organ injury is defined as severe asymptomatic hypertension or hypertensive urgency [13]. This entity often occurs among patients who have been non-adherent with their chronic antihypertensive drug regimen [20].

3. Mechanisms

The common pathophysiologic scenario involved in the acute target-organ dysfunction during a severe elevation of BP is not clearly understood [20]. The initial steps in this disease process is the failure of normal autoregulation, the release of humoral vasoconstrictors from the wall of a stressed vessel, and an abrupt rise in systemic vascular resistance [21–23]. More specifically, acute and marked elevation in BP overwhelms the autoregulation of the endothelial control of vascular tone, leading to endothelial damage with vascular permeability, recruitment of inflammatory mediators, and activation of the coagulation cascade (activation of platelets, and deposition of fibrin) [21–23]. The cycle of further vascular injury and autoregulatory dysfunction promotes hypoperfusion (end-organ ischemia) with subsequent target-organ dysfunction [21–23].

The above picture is further complicated in patients with COVID-19. The direct invasion of endothelial cells by SARS-CoV-2 promotes cell injury, microvascular inflammation, endothelial exocytosis, and endothelitis [24,25] leading to acute respiratory distress syndromes (ARDS) [24,25]. Excessive production of pro-inflammatory cytokines leads to ARDS aggravation and widespread tissue damage resulting in multi-organ failure [26–29]. Furthermore, some observations support a direct effect of SARS-CoV-2 invasion on the homeostatic regulation of the vascular system and BP [30–33].

The angiotensin-converting enzyme-2 (ACE2) is a catalytic enzyme which is recognized as the receptor for the entry point for the SARS-CoV-2 virus on host cells [34,35]. At the same time, ACE2 receptors play a key role in the modulation of the balance between vasoconstriction and vasodilatation, and in the regulation of the cardiovascular and renal function [30–32,36].

Indeed, ACE2 receptors are regulators of the renin-angiotensin-aldosterone-system (RAAS) by catalyzing the cleavage of angiotensin I into angiotensin1-9, and angiotensin II into the vasodilator angiotensin1-7. Angiotensin II is a potent vasoconstrictor, a stimulant of aldosterone release, and a promoter of adverse reactions including hypercoagulability, endothelial dysfunction, enhanced inflammation, and increased oxidative stress. On the contrary, angiotensin1-7 exerts several protective cardiovascular effects by the inhibition of angiotensin II-induced signaling, vasodilatation, sympathetic modulation, and restoration of endothelial function [30,31]. Remarkably, the interaction between ACE2 and SARS-CoV-2 is associated with the phenomenon of ACE2 downregulation, with internalization of ACE2 receptor into cells [37,38] and consequent substantial loss of ACE2 receptor enzymatic activity from the external site of the membrane. These mechanisms lead to less angiotensin II inactivation and less generation of antiotensin1-7 (imbalance between angiotensin II overactivity and angiotensin1-7 deficiency) which may trigger inflammation, thrombosis, and, notably, a rise in BP (Figure 1) [30–32].

4. Pharmacotherapy of hypertensive emergencies

There are only few data on the treatment of these conditions during the acute phase of COVID-19. A case report has been reported of a primi mother with COVID-19 who presented with
diarrhea and very high BP and evolved toward placental abruption [39].

In this setting, we strongly recommend to follow the indications from current Guidelines for the treatment of hypertensive emergencies [13]. As depicted in Table 1, the type of target organ damage is the main determinant of the choice of BP-lowering drugs, target BP, and timeframe by which reduction in BP should achieved [13].

For most hypertensive emergencies, mean arterial pressure (MAP) should be reduced gradually (by approximately 10 to 20% in the first hour and by a further 5 to 15% over the next 23 hours) [40]. The target is to reduce systolic BP <180 mmHg and diastolic BP <120 mmHg for the first hour. In the next 23 hours, systolic/diastolic BP should be reduced to <160/110 mmHg [40].

However some exceptions to gradual BP lowering over the first day include the acute phase of an ischemic stroke [41], aortic dissection [42], and intracerebral hemorrhage [43].

An example of hypertensive emergency (acute cardiac injury with elevated values of systolic BP) during the acute phase of COVID-19 is depicted in Figure 2. Specifically, a 70-year old white man, hospitalized for COVID-19 pneumonia, developed after 3 days from admission a hypertensive emergency with Non-ST-Elevation Myocardial Infarction (NSTEMI). Treatments with infusion of nitroglycerin and labetalol were used to lower heart rate and BP values with consequent normalization of electrocardiographic examination. A RAAS blocker (telmisartan 80 mg once daily) was also added during hospitalization to attain BP target.

**Table 1.** Types of acute hypertension-mediated organ damage, target BP, time line and first line treatments (see text for details).

![Figure 1. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) interaction with angiotensin converting enzyme 2 (ACE2) receptors. After the invasion of SARS-CoV-2, the binding to membranal ACE2 is associated with the phenomenon of downregulation and progressive loss of catalytic activities. The process leads to a marked imbalance between angiotensin II overactivity and angiotensin-II deficiency, triggering rise in BP (see text for details).](image)

| Hypertensive emergency | Timeline | Target BP | First line treatments |
|------------------------|----------|-----------|-----------------------|
| Malignant hypertension | Several hours | MAP −20% to −25% | Labetalol |
| Hypertensive encephalopathy | Immediate | MAP −20% to −25% | Nicardipine |
| Acute hemorrhagic stroke | Immediate | SBP < 180 mmHg (and >130 mmHg) MAP −15% | Labetalol |
| Acute ischemic stroke* | 1 hour | SBP < 140 mmHg | Labetalol |
| Acute coronary event | Immediate | SBP < 140 mmHg | Labetalol, Nicardipine |
| Acute cardiogenic pulmonary edema | Immediate | SBP < 120 mmHg and HR < 60 bpm | Nitroglycerin, Nicardipine |
| Acute aortic disease | Immediate | SBP < 160 mmHg and DBP < 105 bpm | Nicardipine, Magnesium sulphate |
| Eclampsia and severe pre-eclampsia/HELLP | Immediate | SBP >185 mmHg or DBP >110 mmHg, acute ischemic stroke and SBP >220 mmHg or DBP > 120 mmHg, acute hemorrhagic stroke and SBP > 180 mmHg. | Esmolol |

DBP = diastolic blood pressure; HELLP = hemolysis, elevated liver enzymes and low platelets; MAP = mean arterial pressure; SBP = systolic blood pressure.

* = acute ischemic stroke with indication for thrombolytic therapy and
5. Pharmacotherapy of hypertensive urgencies

In hypertensive urgencies, BP should be reduced over a period of hours to days with slower reductions in elderly patients to avoid and increased risk of cerebral or myocardial ischemia resulting from excessively rapid reduction of BP [13].

Systolic/diastolic BP should usually be lowered to <160/<100 mmHg and MAP should not be lowered by more than 25 to 30% over the first two to four hours [13,20]. In the long-term, BP should be reduced further according to current Guidelines [44,45].

In the context of COVID-19, the management of hypertensive patients and the choice of antihypertensive medications deserve specific consideration. Several effective BP-lowering drugs (including beta-blockers, diuretics, RAAS blockers, and calcium channel blockers) have been evaluated in COVID-19 patients. Taken together, the results of clinical studies suggest that some drug classes might offer specific benefits in COVID-19 patients with hypertension.

5.1. Diuretics

Only a retrospective study in 971 hypertensive patients specifically evaluated the use of diuretics and its association with various outcomes of COVID-19 [46]. In logistic regression model adjusted by propensity score, the use of diuretics was associated with higher risk of cardiac injury (OR = 2.65, 95% CI: 1.25–5.62, p = 0.011) vs. non-users of diuretics [46]. The basic mechanisms of such adverse reaction remain substantially unclear.

5.2. Calcium-channel-blockers

Zhang and coworkers reported that a panel of nine clinically approved channel blockers (benidipine, amlodipine, cilnidipine, nicardipine, nifedipine, isradipine, nisoldipine, felodipine, and nifedipine) may inhibit the post-entry replication events of SARS-CoV-2 in vitro, among which benidipine, amlodipine, cilnidipine, and nicardipine showed more significant inhibition effect [47].

These agents, when combined with chloroquine, provided an enhancement of the anti-SARS-CoV-2 efficacy [47]. The same Authors analyzed retrospective data of hospitalized COVID-19 patients with hypertension. They revealed that therapy with amlodipine was associated with a decreased rate of all-cause mortality [47].

Similarly, a retrospective review was conducted on calcium-channel-blockers use in hospitalized COVID-19 patients to evaluate the potential effects on survival and progression of disease leading to intubation and mechanical ventilation [48]. Patients treated with a calcium-channel-blocker were more likely to survive than those not treated with a calcium-channel-blocker. Furthermore, patients treated with calcium-channel-blockers were also significantly less likely to undergo intubation and mechanical ventilation [48].

Such results were not confirmed by a clinical trial in hospitalized patients with COVID-19 and primary hypertension in which 80 patients were randomized to losartan (25 mg, twice a day) or amlodipine (5 mg per day). The main outcomes were 30-day mortality rate and length of hospital stay [49]. The length of hospital stay in losartan and amlodipine groups was 4.57 and 7.30 days, respectively (p = 0.085). The length of ICU admission in losartan and amlodipine group was 7.13
Table 2. Observational studies in COVID-19 patients treated or not treated with ACE-inhibitors or angiotensin II receptor blockers. Reproduced from ref [30]. with permission of Wolters Kluwer Health.

| Study       | Number of patients | Ref. | Main results                                                                 |
|-------------|--------------------|------|--------------------------------------------------------------------------------|
| Peng et al  | 112                | [60] | The proportion of patients treated with ACEIs/ARBs did not differ between survivors and nonsurvivors, as well as between those with or without severe illness. |
| Zhang et al | 1,128              | [58] | Treatment with ACEIs/ARBs was associated with lower risk of all-cause death (unadjusted mortality for ACEIs/ARBs group vs non-ACEIs/ARBs group: 3.7% vs 9.8%; P = 0.01). In a multivariable analysis, the risk for all-cause death was lower in the ACEIs/ARBs group vs the non-ACEIs/ARBs group (adjusted HR, 0.42 [95% CI, 0.19–0.92]; P = 0.03). |
| Richardson et al | 5,700 | [6] | Death rate during hospitalization did not differ significantly between patients treated or not treated with ACEIs/ARBs before hospitalization (31.4% vs 26.7%). |
| Li et al.   | 1,178              | [61] | Treatment with ACEIs/ARBs did not differ between patients with severe vs non severe illness (32.9% vs 30.7%; P = 0.645), as well between non survivors and survivors (27.3% vs 33.0%; P = 0.34) |
| Yang et al. | 251                | [62] | Treatment with ACEIs/ARBs was associated with a not significant lower proportion of critical illness (9.3% vs 22.9%; P = 0.061) and death (4.7% vs 13.3%; P = 0.216). |
| Mancia et al. | 37,031 | [63] | Treatment with ACEIs/ARBs was not associated with an increased risk of severe or fatal course of the disease (adjusted OR, 0.83 [0.63–1.10] for ARBs and 0.91 [0.69–1.21] for ACEIs). |
| Mehra et al. | 8,910              | [59] | Treatment with ACEIs, but not with ARBs, was associated with a significantly lower risk of in-hospital death (2.1% vs 6.1%; OR, 0.33 [0.20–0.54]). |
| Reynolds et al. | 12,594 | [64] | Treatment with ACEIs/ARBs was not associated with an increased likelihood of COVID-19 test positivity (58.1% vs 57.7%) or with the risk of severe illness (24.8% vs 24.9%). |
| Mehta et al. | 18,472             | [65] | Treatment with ACEIs/ARBs was not associated with an increased likelihood of COVID-19 test positivity (OR, 0.97 [0.81–1.15]). |
| Conversano et al. | 191 | [66] | Age, heart failure, and chronic kidney disease, but not treatment with ACEIs/ARBs, were associated with an increased risk of death. |

COVID-19 = Coronavirus infectious disease-2019; CVD = cardiovascular disease; ACEIs = Angiotensin converting enzyme inhibitors; ARBs = angiotensin II receptor blockers; HR = hazard ratio; OR = Odds Ratio.

and 7.15 days, respectively (p = 0.994). The 30-day mortality was also similar between the two arms (p = 0.241) [49].

5.3. Beta-blockers

It has been suggested that the use of beta-blockers might reduce the SARS-CoV-2 invasion through a direct effect on ACE2 expression (downregulation) [50]. Furthermore, potential protective mechanisms of beta-adrenergic receptor blocker treatment in COVID-19 include the reduction of interleukin-6 (IL-6), pro-inflammatory cytokines, and hyper-coagulation state [50]. Nonetheless, the use of beta-blockers was not associated with a lower likelihood of a positive test among 12,594 patients tested for COVID-19 [51].

A collaborative Dutch/German study investigating 1134 patients hospitalized for Covid-19 showed that beta-blocker treatment significantly reduced the risk of major outcome [52].

Similarly, a multicenter retrospective study including 2190 patients with COVID-19 indicated that beta-blockers might be beneficial, even after adjustment for age, gender, baseline BP, and coexisting medical conditions [53].

5.4. ACE-inhibitors and angiotensin receptor blockers

RAAS-blockers may up-regulate ACE2 [54]. Thus, an increased risk of SARS-CoV-2 infection during treatment with these agents has been hypothesized [54]. However, the position held by Scientific Societies and experts in the area is that discontinuation of RAAS-blockers is not supported by evidence and, conversely, might be unsafe [55–57].

A systematic review from our group showed that available studies do not show any signal of harm associated with ACE-inhibitors or angiotensin-receptor-blockers (ARBs) in patients with COVID-19 (Table 2) [30]. Interestingly, a study conducted in hypertensive patients hospitalized for COVID-19, mortality at 28 days was lower among patients taking ACE-inhibitors or ARBs than among patients not receiving these drugs (3.7% vs. 9.8%; p = 0.01) [58]. Moreover, Mehra and coworkers, demonstrated that treatment with ACE-inhibitors, but not with ARBs, was associated with a significantly lower risk of in-hospital death (2.1% vs. 6.1%; OR 0.33, 95% CI: 0.20 to 0.54) [59].

A meta-analysis including a total of 1808 patients with hypertension and COVID-19 recruited in 6 studies showed that the administration of ACE-inhibitors or ARBs had positive effect on reducing D-dimer and the number of people with fever [67].

More recently, a systematic review and meta-analysis of 52 studies including 101,949 patients with COVID-19 evaluated the outcome among who did and did not receive ACE-inhibitors or ARBs [68]. After multivariable adjustment, the Authors demonstrated a significantly decreased risk of mortality and severe adverse events among patients who received ACE-inhibitors or ARBs compared with patients who did not [68]. Of note, subgroup analysis showed that patients with hypertension had a significant decrease in the risk of death and severe adverse outcomes among patients receiving ACE-inhibitors or ARBs (in both unadjusted and adjusted models) [68].

6. Conclusion

Despite the association of severe COVID-19 with hypertension and the potential importance of hypertensive urgencies and emergencies [69] in this setting, the burden of this condition remains undefined. Recent data from observational studies clearly showed that an elevated BP and a high BP variability during hospitalization for COVID-19 are independently associated with a worse outcome [5,6]. Thus, the use of antihypertensive drugs and their potential impact on outcome in
COVID-19 patients remain a key point. Despite conflicting views in the literature, hypertensive emergencies should be treated according to current Guidelines in the setting of COVID-19 [13]. However, the peculiar mechanisms potentially involved in the pathogenesis of BP elevation in patients with COVID-19 may support the preferential use of RAAS-blockers, beta-blockers, and calcium channel blockers for the treatment of elevated BP during the acute phase of the disease.

7. Expert opinion

Observational studies investigating characteristics of hospitalized patients for SARS-CoV-2 infection have found that the presence of hypertension increases the risk of severe clinical outcomes [1,2]. Acute elevations in BP and uncontrolled in-hospital BP are significant predictors of organ damage and worse outcome in these patients [9]. In particular, hypertension is associated with a more frequent admission to intensive care units, worsening heart failure and mortality in patients hospitalized for COVID-19 [9,10].

Unfortunately, the real burden of elevated BP during the acute phase of COVID-19 remains undefined. Being the evidence still scanty, results of clinical studies focused on the role of different BP-lowering drugs need to be interpreted with caution.

According to current Guidelines [13], only the COVID-19 patients with hypertensive emergencies require a prompt reduction in their markedly elevated BP. Thus, hypertensive emergencies should be treated with intravenous drug administration according to specific features and treatment goals [13]. Conversely, hypertensive urgencies usually require oral drug administration. BP-lowering treatment should be individualized to each patient based on the type and extent of end-organ damage and degree of BP elevation [13].

Some mechanistic studies suggest that RAAS blockers, calcium channel blockers and beta-blockers might be preferred as antihypertensive drugs in patients with COVID-19. Indeed, these drugs have been associated with inhibition of invasion [50] and post-entry replication [47] of SARS-CoV-2, reduction of the cytokines storm [50] and enhancement of the RAAS protective pathway during the infection [70–72]. However, according to available clinical data, there is no final evidence that these drugs are associated with a better outcome.

In particular, some authors theorized that the up-regulation of ACE2 receptors caused by ACE-inhibitors and ARBs might favor the viral invasion [54,73]. However, several large studies conducted so far did not show any signal of harm associated with ACE-inhibitors or ARBs in patients with COVID-19 [30].

There is growing evidence that the blunted ACE2 activity resulting from downregulation of these receptors after viral entry and the resulting imbalance between angiotensin II and angiotensin1-7 may play an important role in conditioning inflammatory, thromboembolic and hemodynamic processes in patients with COVID-19 [30,31,36]. Following this line of evidence, by enhancing ACE2 expression [74–77] and limiting the effects of unopposed angiotensin II on the heart, lungs, and vasculature, RAAS blockers could theoretically play a protective role in patients with COVID-19 infection [30,31,70,71].

As stated above, calcium-channel-blockers and beta-blockers might have a role in COVID-19 patients [53]. In a multicenter study conducted in patients hospitalized for laboratory-confirmed COVID-19, the clinical outcome of patients with COVID-19 was better in patients treated with ARBs, beta-blockers, and calcium-channel blockers [53]. Conversely, diuretics might be particularly detrimental in patients treated with mechanical ventilation at increased positive end expiratory pressure [50,78]. Diuretics could be also associated with a higher risk of cardiac injury [46].

Funding

This manuscript was not funded.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

References

Papers of special note have been highlighted as either of interest (-) or of considerable interest (•) to readers.

1. Grasselli G, Zaninelli A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020 Apr 28;323(16):1574–1581.
2. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061–1069.
3. Angeli F, Marazzato J, Verdeccchia P, et al. Joint effect of heart failure and coronary artery disease on the risk of death during hospitalization for COVID-19. Eur J Intern Med. 2021 Apr 19;89:81–86.
4. Results of a prospective clinical study demonstrating that the combination of HF and CAD exerts a marked detrimental impact on the risk of mortality in hospitalized patients with COVID-19.
5. Centers for Disease Control and Prevention. Science Brief: evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19. [cited 2021 May 15]. https://www.cdc.gov/coronavirus/2019-ncov/science-briefs/underlying-evidence-table.html
6. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with covid-19 in the New York City Area. JAMA. 2020 Apr 22;323(20):2052.
7. Case series of patients with COVID-19 describing the presenting characteristics and outcomes of US patients requiring hospitalization
8. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020 May;94:91–95.
9. Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020 Apr 30;130(4):304–309.
10. Run J, Song Y, Zhuang Z, et al. Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant
hypertension in Wuhan, China. Hypertens Res. 2020 Nov;43 (11):1267–1276.

- Observational clinical study of COVID-19 patients, showing that an exaggerated cardiovascular response with persistently elevated blood pressure (BP) and high BP variability during hospitalization are independently associated with in-hospital mortality, intensive care unit admission, and heart failure.

10. Sreed S, Tadic M, Larsen TH, et al. Coronavirus disease 2019 and cardiovascular complications: focused clinical review. J Hypertens. 2021 Jul 1;39(7):1282–1292.

11. Haynes RB, Kastner M, Wilczynski NL, et al. Developing optimal search strategies for detecting clinically sound and relevant causation studies in EMBASE. BMC Med Inform Decis Mak. 2005 Mar;22 (5):8.

12. McAuley L, Pham B, Tugwell P, et al. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet. 2000 Oct 7;356(9237):1228–1231.

13. Van Den Born BH, Lip GYH, Brugulian-Hitij J, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):37–46.

- Guidelines of the diagnosis and management of hypertensive urgencies and emergencies.

14. Amraoui F, Van Der Hoeven NV, Van Valkengoed IG, et al. Mortality and cardiovascular risk in patients with a history of malignant hypertension: a case-control study. J Clin Hypertens (Greenwich). 2014 Feb;16(2):122–126.

15. Shantsila A, Shantsila E, Beeveres DG, et al. Predictors of 5-year outcomes in malignant phase hypertension: the West Birmingham Malignant hypertension registry. J Hypertens. 2017 Nov;35(11):2310–2314.

16. Angeli F, Verdecchia P, Narducci P, et al. Additive value of standard ECG for the risk prediction of hypertensive disorders during pregnancy. Hypertens Res. 2011 Jun;34(6):707–713.

17. Angeli F, Angeli G, Reboli G, et al. Hypertensive disorders during pregnancy: clinical implication of risk prediction models. J Hypertens. 2011 Dec;29(12):2320–2323.

18. Angeli F, Angeli G, Verdecchia P. Electrocardiographic changes in hypertensive disorders of pregnancy. Hypertens Res. 2014 Nov;37 (11):973–975.

19. Angeli F, Angel G, Verdecchia P. Novel electrocardiographic patterns for the prediction of hypertensive disorders of pregnancy—from pathophysiology to practical implications. Int J Mol Sci. 2015 Aug 7;16(8):18454–18473.

20. Angeli F, Reboli G, Verdecchia P. Hypertensive urgencies and emergencies: misconceptions and pitfalls. Eur J Intern Med. 2020 Jan;71:15–17.

21. Ault MJ, Elliott AG. Pathophysiological events leading to the end-organ effects of acute hypertension. Am J Emerg Med. 1985 Dec;3 (6 Suppl):10–15.

22. Derhaschnig U, Testori C, Riedmuller E, et al. Hypertensive emergencies are associated with elevated markers of inflammation, coagulation, platelet activation and fibrolysis. J Hum Hypertens. 2013 Jun;27(6):368–373.

23. Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000 Jul 29;356(9227):411–417.

24. Lowenstein CJ, Solomon SD. Severe COVID-19 Is a Microvascular Disease. Circulation. 2020 Oct 27;142(17):1609–1611.

25. Libby P, Luscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020 Sep 1;41(32):3038–3044.

26. Chen R, Lan Z, Ye J, et al. Cytokine storm: the primary determinant for the pathophysiological evolution of COVID-19 deterioration. Front Immunol. 2021;12:589095.

27. Coperchini F, Chiovato L, Rotondi M. Interleukin-6, CXCL10 and infiltrating macrophages in COVID-19-related cytokine storm: not one for all but all for one! Front Immunol. 2021;12:668507.

28. Gursoy B, Surmeli CD, Alkan M, et al. Cytokine storm in severe COVID-19 pneumonia. J Med Virol. 2021 May 8;93(9):5474–5480.

29. Rabaan AA, Al-Ahmed SH, and Muhammad J, et al. Role of inflammatory cytokines in COVID-19 patients: a review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm. Vaccines (Basel). 2021 Apr 29;9(5):436. DOI:10.3390/vaccines9050436.

30. Verdecchia P, Cavallini C, Spanevello A, et al. COVID-19: ACE2-centric infective disease? Hypertension. 2020 Aug;76(2):294–299.

- Mechanisms of the the interaction between ACE2 and SARS-CoV-2, explaining the phenomenon of ACE2 downregulation (internalization of ACE2 receptors into cells) with consequent substantial loss of ACE2 receptor activity from the external side of the membrane.

31. Verdecchia P, Cavallini C, Spanevello A, et al. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020 Jun;76:14–20.

- Opinion paper showing the interations of SARS-CoV-2 with ACE2 receptors.

32. Angeli F, Reboli G, Verdecchia P. Ageing, ACE2 deficiency and bad outcome in COVID-19. Clin Chem Lab Med. 2021 Jun 14;59 (10):1607–1609.

33. Angeli F, Verdecchia P, Reboli G. RAAS Inhibitors and Risk of Covid-19. N Engl J Med. 2020 Nov 12;383(20):1990–1991.

34. Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020 Apr;46 (4):586–590.

35. Verdecchia P, Reboli G, Cavallini C, et al. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus]. G Ital Cardiol (Rome). 2020 May;21 (5):321–327.

36. Verdecchia P, Angeli F, and Reboli G. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus. J Hypertens. 2020;38(6):1190–1191. DOI:10.1097/ HJH.0000000000002469.

37. Tang Q, Wang Y, Ou L, et al. Downregulation of ACE2 expression by SARS-CoV-2 worsens the prognosis of KIR and KIRP patients via metabolism and immunoregulation. Int J Biol Sci. 2021;17(8):1925–1939.

38. Lecarpentier Y, Vallee A. The key role of the level of ACE2 gene expression in SARS-CoV-2 infection. Aging (Albany NY). 2021 Jun 11;13(11):14552–14556.

39. Bandara S, Ruwanpathirana A, Nagodawithana D, et al. Hypertensive Crisis in Pregnancy with COVID19: confirmed with rt-PCR for Nasopharyngeal Swab. Case Rep Obstet Gynecol. 2020;2020:886952.

40. Elliott WJ. Clinical features in the management of selected hypertensive emergencies. Prog Cardiovasc Dis. 2006 Mar-Apr;48(5):316–325.

41. Powers WJ, Rabinstein AA, Ackerton T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019 Dec;50(12):e344–e418.

42. Li JZ, Eagle KA, Vaishnava P. Hypertensive and acute aortic syndromes. Cardiol Clin. 2013 Nov;31(4):493–501, vii.

43. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral Hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015 Jul;46 (7):2032–2060.

44. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020 Jun;75(6):1334–1357.

45. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020 Jun;38(6):982–1004.

46. Yuan Y, Liu D, Zeng S, et al. In-hospital use of ACEI/ARB is associated with lower risk of mortality and critical illness in COVID-19 patients with hypertension. J Infect. 2020 Nov;81(5):816–846.
47. Zhang LX, Sun Y, Zeng H, et al. Calcium channel blocker amldipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. Cell Discov. 2020 Dec 22;6(1):96.

48. Solaimanzadeh I. Nifedipine and amldipine are associated with improved mortality and decreased risk for intubation and mechanical ventilation in elderly patients hospitalized for COVID-19. Cureus. 2020 May 12;12(5):e8069.

49. Nouri-Vasheh M, Kalami N, Zand R, et al. Comparison of losartan and amldipine effects on the outcomes of patient with COVID-19 and primary hypertension: a randomised clinical trial. Int J Clin Pract. 2021 Jun;75(6):14124.

50. Kjeldsen SE, Narkiewicz K, Burnier M, et al. Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers. Blood Press. 2021 Feb;30(1):1–3.

• Investigation on the effects of beta-blockers on the reduction of the SARS-CoV-2 invasion.

51. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-Angiotensin aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020 Jun 18;382(25):2441–2448.

52. Pinto-Sietsma SJ, Flosdorff M, Buchholz VR, et al. Antihypertensive drugs in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):415–416.

53. Yan F, Huang F, Xu J, et al. Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients. Cell Discov. 2020 Oct 29;6(1):77.

• Multicenter retrospective study to examine the potential association between clinical outcomes, disease severity, and clinical characteristics with the use of different classes of antihypertensive drugs.

54. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens. 2020;38(5):1–2. 10.1097/HJH.0000000000002450.

55. Bavishi C, Maddox TM, Messerli FH. Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers. JAMA Cardiol. 2020 Apr 3;5(7):745.

56. Danser AHJ, Epstein M, Battle D, et al. Renin-Angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020 Mar 25;75(6):1382–1385.

HYPERTENSIONNAHA1.2015082

57. Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020 Mar 20;41(19):1801–1803.

58. Zhang P, Zhu L, and Cai J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and Angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671-1681.

59. Mehra MR, Desai SS, Kuy S, et al. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020 May 1;382(26):2582.

60. Peng YD, Meng K, Guan HQ, et al. [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 2;48:E004.

61. Li J, Wang X, Chen J, et al. Association of Renin-Angiotensin System inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020 Apr 23;5(7):825.

62. Yang G, Tan Z, Zhou L, et al. Effects of ARBs and ACEIs on virus infection, inflammatory status and clinical outcomes in COVID-19 patients with hypertension: a single center retrospective study. Hypertension. 2020 Apr 29;76(1):51–58.

63. Mancia G, Rea F, Ludergiani M, et al. Renin-Angiotensin aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020 May 1;382(25):2431–2440.

64. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-Angiotensin aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020 May 1;382(25):2441–2448.10.1056/NEJMoa2008975

65. Mehta N, Kalra A, Nowacki AS, et al. Association of Use of Angiotensin-Converting enzyme inhibitors and Angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 May 5;5(9):1020.

66. Conversano A, Melillo F, Napolano A, et al. RAAs inhibitors and outcome in patients with SARS-CoV-2 pneumonia. A case series study. Hypertension. 2020 May 8;76(2). 10.1161/HYPERTENSIONAHA.120.15312.

67. Xue Y, Sun S, Cai J, et al. Effects of ACEI and ARB on COVID-19 patients: a meta-analysis. J Renin Angiotensin Aldosterone Syst. 2020 Oct-Dec;21(4):1470322020981321.

68. Baral R, Tsampasian V, Debski M, et al. Association Between Renin-Angiotensin-Aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA Network Open. 2021 Mar 1;4(3):e213594.

69. Roubanthisuk W, Wongsurin U, Buranakijaroen P. Hypertensive emergencies remain a clinical problem and are associated with high mortality. J Med Assoc Thai. 2010 Jan;93(Suppl 1):554–61.

70. Kreutz R, Algharably EAE, Azizi M, et al. Hypertension, the reninangiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020 Aug 1;116(10):1688–1699.

71. Sharma RK, Stevens BR, Obukhov AG, et al. ACE2 (AngiotensinConverting Enzyme 2) in cardiopulmonary diseases: ramifications for the control of SARS-CoV-2. Hypertension. 2020 Sep;76(3):651–661.

72. Angeli F, Masnaghetti S, Visca D, et al. Severity of COVID-19: the importance of being hypertensive. Monaldi Arch Chest Dis. 2020 May 20;90(2). 10.4081/monaldi.2020.1372.

73. Fang L, Karakulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Apr;8(4):e21.

74. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensinconverting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005 May 24;111(20):2605–2610.

75. Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004 May;43(5):970–976.

76. Karram T, Abbasi A, Keidar S, et al. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1351–8.

77. Ocana MP, Godoy I, Jalil JE, et al. Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension. 2006 Oct;48(4):572–578.

78. Tosaki V, Zakynthinos GE, Mantzarlis K, et al. Increased mortality among hypertensive COVID-19 patients: pay a closer look on diuretics in mechanically ventilated patients. Heart Lung. 2020 Nov - Dec;49(6):894–895.